Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kura Oncology (KURA) Shares Outstanding (Weighted Average) (2022 - 2026)

Kura Oncology has reported Shares Outstanding (Weighted Average) over the past 5 years, most recently at $88.6 million for Q1 2026.

  • Quarterly Shares Outstanding (Weighted Average) rose 1.37% to $88.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $88.6 million through Mar 2026, up 1.37% year-over-year, with the annual reading at $86.2 million for FY2024, 17.66% up from the prior year.
  • Shares Outstanding (Weighted Average) was $88.6 million for Q1 2026 at Kura Oncology, up from $840585.0 in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $88.6 million in Q1 2026 and troughed at $840585.0 in Q3 2025.
  • The 5-year median for Shares Outstanding (Weighted Average) is $83.9 million (2024), against an average of $73.6 million.
  • Year-over-year, Shares Outstanding (Weighted Average) grew 25.37% in 2024 and then plummeted 99.02% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $67.0 million in 2022, then grew by 9.31% to $73.2 million in 2023, then increased by 17.66% to $86.2 million in 2024, then plummeted by 99.02% to $840585.0 in 2025, then soared by 10441.47% to $88.6 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Shares Outstanding (Weighted Average) are $88.6 million (Q1 2026), $840585.0 (Q3 2025), and $87.6 million (Q2 2025).